5 results about "Triazolopyridine" patented technology

Provided are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

The application discloses a triazolopyridine bromodomain-containing protein 4 (BRD4) small molecule inhibitor and a preparation method and application thereof, a compound or a pharmaceutically acceptable salt or a racemate thereof, the general formula of which is shown as formula (I). The novel synthetic triazolopyridine compound effectively regulates the occurrence and development process of related diseases by inhibiting the activity of BRD4 protein. In addition to the advantage of inhibiting the activity of BRD4 protein, the compound has good water solubility and liver microsomal stability, which means that it can be better absorbed and distributed in the body, thereby improving the therapeutic effect. The compound also has good drugability, so that it can be better applied to various inflammatory, autoimmune diseases and tumor drugs. The application provides a new choice for the treatment of related diseases and is expected to play an important role in clinical practice.

The present application relates to the field of artificial board, and discloses a mildew-proof and water-resistant bamboo-based artificial board and a preparation method thereof, wherein the board blank of the artificial board is formed by bamboo shaving glue mixing and paving; the components for glue application include melamine, formaldehyde, modified bamboo powder, modified nano silicon dioxide, plant oil acid and water; the modified bamboo powder is made by grafting modified silane coupling agent with bamboo powder; the modified silane coupling agent is made by reacting functional modifier obtained by the reaction of 3-chloro-2-hydrazine pyridine intermediate made from 3-chloro-2-hydrazine pyridine and carbon disulfide, hydrophobic modified ultraviolet absorber made from 5-chloro-2-(2',4'-dihydroxyphenyl)-2H-benzotriazole and glycidyl ester tertiary carbonic acid, and p-phenylenediamine, and then reacting with vinyl trimethoxysilane; the modified nano silicon dioxide is made by modifying with silicon-phosphorus coupling modifier obtained from DOPO and vinyl triethoxysilane and tetraethyl orthosilicate, so as to prepare the artificial board with good ultraviolet resistance, antibacterial and mildew-proof property, water resistance and flame retardance.

Provided are compounds of Formula I, Formula Ib or Formula Ic and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, Formula Ib or Formula Ic, pharmaceutical compositions comprising compounds of Formula I, Formula Ib or Formula Ic, and methods of using these compounds to treat hepatic steatosis, non-alcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

A crystal form of a triazolopyridine-substituted indazole compound and a preparation method thereof, and specifically discloses a crystal form of a compound shown in formula (I) and a preparation method thereof.